Evaluation of the pain intensity of pain and quality of life of patients with osteoporosis diagnosis and teriparatide treatment

Evaluación de la intensidad del dolor y calidad de vida del paciente con diagnóstico de osteoporosis y tratamiento con teriparatida

##plugins.themes.bootstrap3.article.main##

Alejandro Pinzón Tovar
Eduard Mauricio Díaz
Marcela Castro
Abstract

A descriptive, retrospective study to determine whether treatment with recombinant parathyroid hormone (teriparatide)reduces pain in patients with osteoporosis, in the endocrinology unitat the Military Hospital in Colombia in 008. Objectives: 1) to describe demographic  aspects of osteoporosis patients managed with teriparatide.2) to determine frequency of patients requiring analgésic adjuvant therapy for the management of pain associated withosteoporosis. 3) to determine whether the use of teriparatide reduced pain in patients with osteoporosis. Materials and Methods: From twenty patients with osteoporosis who received teriparatide,12 were included in the study in a period from January to December 2008. To evaluate the quality of life and pain intensity,the SF36 questionnaire and visual analog pain scale was used, respectively. All data from the survey sand the SF36 form, were stored in data bases using the program Excel 2011. A descriptive statistical analysis was performed  using the frequency representation as a percentage. To determine differences in the frequency of occurrence of an event,Chi2 test was used. P < 0.05 was considered as significant. Results: Teriparatide treatment significantly decreased frequency of patients requiring analgésica djuvant therapy with NSAIDs and opiates at 6 months follow-up (P=0.04,Chi2). Conclusions: results suggest a beneficial effect of pain relief and quality of life with treatment for osteoporosis with teriparatide. Conclusions: results suggest a beneficial effect of pain relief and quality of life with treatment for osteoporosis with teriparatide.

Keywords

Downloads

Download data is not yet available.

##plugins.themes.bootstrap3.article.details##

Author Biographies / See

Alejandro Pinzón Tovar, Universidad Militar Nueva Granada - Hospital Militar de Colombia

Médico internista, Universidad Surcolombiana Neiva. Endocrinólogo, Universidad Militar Nueva Granada - Hospital Militar de Colombia.

Eduard Mauricio Díaz, Universidad Surcolombiana Neiva

Residente de III año Medicina Interna.

Marcela Castro, Universidad Surcolombiana

Residente de III año Medicina Interna.
References

1. Warriner A, Saag K, Osteoporosis Diagnosis and Medical Treatment. Orthop Clin N Am 44. 2013:125-135.

2. Rachner T, Khosla S, Hofbauer L, Osteoporosis: now and the future. Lancet 2011;377:1276-87.

3. Cauley J, Public Health Impact of Osteoporosis. J Gerontol A Biol Sci Med Sci 2013;68(10):1243-1251.

4. Eriksen EF, Halse J, Moen MH. New developments in the treatment of osteoporosis. Acta Obstet Gynecol Scand 2013;92:620-636.

5. Cosman F, Lane NE, Bolognese MA, et al. Effect of transdermal teriparatide administration on bone mineral density in postmenopausal women. J Clin Endocrinol Metab 2010;95:151e8.

6. Appelman-Dijkstra N, Papapoulos S, Novel approaches to the treatment of osteoporosis. Best Pract Res Clin Endocrinol Metab 28. 2014:843-857.

7. Pinkerton J, Thomas S, Dalkin A, Osteoporosis Treatment and Prevention for Postmenopausal Women: Current and Future Therapeutic Options. Clin Obstet Gynecol. 2013;56(4):711-721.

8. Baron R, Hesse E, Update on Bone Anabolics in Osteoporosis Treatment:Rationale, Current Status, and Perspectives. J Clin Endocrinol Metab, 2012;97:311-325.

9. Tella S, Gallagher JC, Prevention and treatment of postmenopausal osteoporosis. J Steroid Biochem Mol Biol 142. 2014:155-170.

10. Cosman F. Combination therapy for osteoporosis: a reappraisal. BoneKEy Rep 2014: 3. Article No. 518.

11. Augustine M, Horwitz M, Parathyroid Hormone and Parathyroid Hormone-Related Protein Analogs as Therapies for Osteoporosis. Curr Osteoporos Rep, 2013;11:400-406.

12. Finkelstein, J. S. Effects of teriparatide, Alendronate, or Both on Bone Turnover in Osteoporotic Men. J Clin Endocrinol Metab 2006;91:2882-2887.

13. Modi A, Sajjan S, Gandhi S. Challenges in implementing and maintaining osteoporosis therapy. International Journal of Women’s Health 2014;6:759-769.

14.Uihlein A, Leder B, Anabolic Therapies for Osteoporosis. Endocrinol Metab Clin N Am 41, 2012; pp. 507-525.

15. Tella S, Gallagher J, Biological agents in management of osteoporosis. Eur J Clin Pharmacol, 2014;70:1291-1301.

16. Das S, Crockett J, Osteoporosis - a current view of pharmacological prevention and treatment. Drug Design, Development and Therapy 2013;7:435-448.

17. Hernlund E, Svedbom A, Ivergård M, Compston J, Cooper C, Stenmark J, ”etc”. Osteoporosis in the European Union: medical management, epidemiology and economic burden. Arch Osteoporos, 2013;8:136.

18. M. C. Nevitt. Reduction in the risk of developing back pain persists at least 30 months after discontinuation of teriparatide treatment: a meta-analysis. Osteoporos Int, 2006;17:1630-1637.

19. Manuele, S. The teriparatide in the treatment of severe senile osteoporosis. Arch. Gerontol. Geriatr. 2007; 1:249-258.

OJS System - Metabiblioteca |